儿童及青年分化型甲状腺癌放射性碘治疗与第二原发恶性肿瘤风险的关联
该研究基于美国九大SEER登记处(1975-2017)数据,评估儿童及青年分化型甲状腺癌(DTC)患者接受放射性碘(RAI)治疗后第二原发恶性肿瘤的风险。在27050例≥5年生存者中,RAI与实体恶性肿瘤风险升高相关(RR=1.23;95%CI 1.11-1.37);在32171例≥2年生存者中,RAI与血液系统恶性肿瘤风险升高相关(RR=1.51;95%CI 1.08-2.01)。结论提示RAI与多种实体癌及白血病风险升高相关,支持对该人群进行长期监测。
要点
- 儿童及青年DTC幸存者中,RAI治疗与实体恶性肿瘤风险升高相关(RR=1.23;95%CI 1.11-1.37)。
- RAI与血液系统恶性肿瘤风险升高相关(RR=1.51;95%CI 1.08-2.01),包括白血病(RR=1.92;95%CI 1.04-3.56)。
- ≥20年DTC生存者中实体癌和女性乳腺癌风险最高(RR=1.47和1.46),支持长期监测。
核心结论
- 除白血病外,儿童及青年DTC的RAI治疗与多种实体癌风险升高相关,尤其在暴露后20年以上,支持对这些患者进行长期监测。
研究设计与样本
- 基于美国九个SEER癌症登记处(1975-2017)数据的队列研究,采用Poisson回归估计RAI(是 vs 否或未知)相关的实体和血液系统恶性肿瘤相对风险(RR)。
- 分析纳入45岁前诊断的非转移性DTC≥5年生存者27050例(中位随访15年)和≥2年生存者32171例。
主要发现
- 27050例≥5年生存者中,45%接受RAI治疗,RAI与实体恶性肿瘤风险升高相关(RR=1.23;95%CI 1.11-1.37)。
- 子宫癌风险升高(RR=1.55;95%CI 1.03-2.32);涎腺癌(RR=2.15;95%CI 0.91-5.08)、胃癌(RR=1.61;95%CI 0.70-3.69)、肺癌(RR=1.42;95%CI 0.97-2.08)和女性乳腺癌(RR=1.18;95%CI 0.99-1.40)风险未达统计学显著。
- ≥20年DTC生存者中,总实体癌和女性乳腺癌(最常见的癌症类型)风险最高(RRsolid=1.47;95%CI 1.24-1.74;RRbreast=1.46;95%CI 1.10-1.95)。
- 32171例≥2年生存者中,RAI与血液系统恶性肿瘤风险升高相关(RR=1.51;95%CI 1.08-2.01),包括白血病(RR=1.92;95%CI 1.04-3.56)。
- 估计儿童及青年DTC生存者中6%的实体恶性肿瘤和14%的血液系统恶性肿瘤可能归因于RAI。
临床怎么用
- 作者认为研究结果支持对儿童及青年DTC幸存者进行长期监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since the 1980s, both the incidence of differentiated thyroid cancer (DTC) and use of radioactive iodine (RAI) treatment increased markedly. RAI has been associated with an increased risk of leukemia, but risks of second solid malignancies remain unclear. We aimed to quantify risks of second malignancies associated with RAI treatment for DTC in children and young adults, who are more susceptible than older adults to the late effects of radiation. METHODS: Using nine US SEER cancer registries (1975-2017), we estimated relative risks (RRs) for solid and hematologic malignancies associated with RAI (yes v no or unknown) using Poisson regression among ≥ 5- and ≥ 2-year survivors of nonmetastatic DTC diagnosed before age 45 years, respectively. RESULTS: Among 27,050 ≥ 5-year survivors (median follow-up = 15 years), RAI treatment (45%) was associated with increased risk of solid malignancies (RR = 1.23; 95% CI, 1.11 to 1.37). Risks were increased for uterine cancer (RR = 1.55; 95% CI, 1.03 to 2.32) and nonsignificantly for cancers of the salivary gland (RR = 2.15; 95% CI, 0.91 to 5.08), stomach (RR = 1.61; 95% CI, 0.70 to 3.69), lung (RR = 1.42; 95% CI, 0.97 to 2.08), and female breast (RR = 1.18; 95% CI, 0.99 to 1.40). Risks of total solid and female breast cancer, the most common cancer type, were highest among ≥ 20-year DTC survivors (RRsolid = 1.47; 95% CI, 1.24 to 1.74; RRbreast = 1.46; 95% CI, 1.10 to 1.95). Among 32,171 ≥ 2-year survivors, RAI was associated with increased risk of hematologic malignancies (RR = 1.51; 95% CI, 1.08 to 2.01), including leukemia (RR = 1.92; 95% CI, 1.04 to 3.56). We estimated that 6% of solid and 14% of hematologic malignancies in pediatric and young adult DTC survivors may be attributable to RAI. CONCLUSION: In addition to leukemia, RAI treatment for childhood and young-adulthood DTC was associated with increased risks of several solid cancers, particularly more than 20 years after exposure, supporting the need for long-term surveillance of these patients.
引用
- Pasqual E, Schonfeld S, Morton LM, et al. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies. J Clin Oncol. 2022. PMID: 35044839. doi:10.1200/JCO.21.01841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。